| Literature DB >> 25099929 |
Manuela Oliveira1, Filipa Rocha Dias, Constança Pomba.
Abstract
BACKGROUND: Escherichia coli is the most common uropathogen involved in urinary tract infection (UTI). Virulence of strains may differ, and may be enhanced by antimicrobial resistance and biofilm formation, resulting in increased morbidity and recurrent infections. The aim of this study was to evaluate the in vitro biofilm forming capacity of E. coli isolates from dogs with UTI, by using fluorescent in situ hybridization, and its association with virulence genes and antimicrobial resistance.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25099929 PMCID: PMC4132243 DOI: 10.1186/1756-0500-7-499
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Biofilm production and virulence and β-lactamase genes presence in 66 isolates from dogs with urinary infections
| | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5 | Negative | - | + | - | - | - | - | - | - | - | - | - |
| 13 | Negative | - | + | - | - | - | - | - | - | - | - | - |
| 21 | Negative | + | + | + | + | + | - | - | - | - | - | - |
| 34 | Negative | - | - | - | - | - | - | - | - | - | - | - |
| 36 | Positive | - | - | - | - | - | - | - | - | - | - | - |
| 43 | Negative | - | - | - | - | - | - | - | - | - | - | - |
| 78 | Positive | + | - | - | - | - | + | + | - | - | + | - |
| 84 | Positive | - | + | - | + | + | - | - | - | - | - | - |
| 88 | Negative | + | + | - | + | + | - | - | - | - | - | - |
| 91 | Negative | - | - | - | - | - | + | + | - | - | + | - |
| 95 | Negative | - | - | - | - | - | + | + | - | - | + | - |
| 99 | Positive | - | - | - | - | - | - | - | - | - | - | - |
| 109 | Positive | + | + | - | + | + | - | - | - | - | - | - |
| 115 | Positive | - | + | - | - | - | - | - | - | - | - | - |
| 125 | Positive | - | - | - | - | - | - | + | - | - | + | - |
| 128 | Negative | - | - | - | - | - | - | - | - | - | - | - |
| 133 | Positive | - | + | - | - | - | - | - | - | - | - | - |
| 134 | Positive | - | + | - | - | - | - | - | - | - | - | - |
| 138 | Positive | + | - | - | - | - | + | - | - | - | - | - |
| 174 | Negative | - | + | - | - | - | - | - | - | - | - | - |
| 179 | Negative | - | + | - | - | - | - | - | - | - | - | - |
| 188 | Negative | - | - | - | - | - | + | + | - | - | + | - |
| 194 | Negative | - | - | - | - | - | + | + | - | - | + | - |
| 207 | Negative | + | + | - | + | + | - | - | - | - | - | - |
| 209 | Negative | + | + | - | + | + | + | - | - | - | - | - |
| 224 | Negative | - | - | - | - | - | + | + | - | - | + | - |
| 226 | Negative | - | - | - | - | - | + | + | - | - | + | - |
| 227 | Positive | - | + | - | + | + | - | - | - | - | - | - |
| 237 | Negative | + | + | - | + | + | + | - | + | - | + | - |
| 238 | Positive | + | + | - | + | + | + | - | + | - | + | - |
| 239 | Positive | + | + | - | + | + | + | - | + | - | + | - |
| 250 | Negative | + | - | - | - | - | - | + | - | - | + | - |
| 251 | Positive | + | + | - | + | + | - | - | - | - | - | - |
| 257 | Negative | + | + | - | + | + | - | + | - | - | + | - |
| 258 | Negative | - | - | - | - | - | - | + | - | - | + | - |
| 271 | Positive | - | - | - | - | - | - | + | - | - | + | - |
| 274 | Positive | - | - | - | - | - | + | + | - | - | + | - |
| 291 | Positive | + | + | - | + | + | - | + | - | - | + | - |
| 304 | Positive | - | + | - | - | - | - | - | - | - | - | - |
| 320 | Negative | - | - | - | - | - | + | + | - | - | + | - |
| 325 | Positive | + | + | - | - | + | + | - | - | - | - | - |
| 327 | Positive | + | - | - | + | + | - | - | - | - | - | - |
| 347 | Negative | - | + | - | + | + | + | - | - | + | + | - |
| 354 | Positive | - | - | - | - | - | + | - | - | + | + | - |
| 372 | Negative | + | + | - | + | + | - | - | - | - | - | - |
| 374 | Negative | + | + | - | + | + | - | - | - | - | - | - |
| 386 | Positive | - | - | + | + | - | - | + | - | - | + | - |
| 401 | Positive | + | + | - | + | + | + | - | - | - | - | - |
| 403 | Positive | - | + | - | - | - | - | + | - | - | + | - |
| 417 | Negative | - | - | - | - | - | - | - | - | - | - | - |
| 443 | Positive | + | + | - | + | + | - | - | - | - | - | - |
| 449 | Positive | - | + | - | - | - | - | - | - | - | - | - |
| 457 | Negative | + | + | - | + | + | - | - | - | - | - | - |
| 461 | Positive | + | + | - | + | + | - | - | - | - | - | - |
| 483 | Positive | - | + | - | - | - | - | - | - | - | - | - |
| 488 | Negative | + | + | - | + | + | - | - | - | - | - | - |
| 505 | Negative | - | - | - | - | - | + | + | - | - | + | - |
| 528 | Positive | - | - | - | - | - | - | - | - | - | - | - |
| 531 | Positive | + | + | - | + | + | + | - | - | - | - | - |
| 536 | Positive | - | + | - | - | - | - | - | - | - | - | - |
| 539 | Positive | - | - | - | - | - | + | + | - | - | + | - |
| 540 | Positive | + | + | - | + | + | - | - | - | - | - | - |
| 553 | Negative | - | - | - | - | - | - | + | - | - | + | - |
| 554 | Positive | + | + | - | + | + | + | - | - | - | - | - |
| 560 | Positive | + | + | - | + | + | - | - | - | - | - | - |
| 566 | Negative | + | - | - | - | - | + | - | - | - | - | - |
| Total (n=) | 35 | 28 | 38 | 1 | 28 | 27 | 23 | 20 | 3 | 2 | 25 | 0 |
| % | 53.0 | 42.4 | 57.6 | 1.5 | 42.4 | 40.9 | 34.8 | 30.3 | 4.5 | 3.0 | 37.9 | 0 |
aVirulence and β-lactamase genes results are adapted from Féria et al. [12] and Pomba et al. [13]; + PCR positive result; − PCR negative result.
Antimicrobial susceptibility to 2 generation fluoroquinolones and its relation with biofilm production in 66 isolates from dogs with urinary infections
| | | ||||
|---|---|---|---|---|---|
| Susceptibility criteria (μg/mL)a | Susceptible; Resistant | ≤ 1; ≥ 4 | ≤ 0.5; ≥ 4 | ≤ 1; ≥ 4 | ≤ 1; ≥ 8 |
| Susceptibility results | Susceptible | 57 (86.4%) | 57 (86.4%) | 57 (86.4%) | 56 (84.8%) |
| | Resistant | 9 (13.6%) | 9 (13.6%) | 9 (13.6%) | 10 (15.2%) |
| Relation with biofilm production | P < 0.05 | P < 0.05 | P < 0.05 | P < 0.05 | |
aIsolates that were categorized as intermediate to the antimicrobial compounds were recorded as susceptible, since the bactericidal activity of these antimicrobials depends of their in vivo concentration and quinolones are known to be concentrated from 100- to 300-fold within the urinary tract (Cohn and others 2003); CIP Ciprofloxacin (CLSI 2014), ENR Enrofloxacin (CLSI 2013), MAR Marbofloxacin (CLSI 2013), OBX Orbifloxacin (CLSI 2013).